Regulatory approval

Published by the Health Service Executive. Approved

As a monotherapy for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.

This is written in the approval document.

Reimbursement

CDS

Citation

Quizartinib Maintenance Therapy, 2026, version number 2, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7019/888_Quizartinib_Maintenance.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) FLT3-ITD Acute Myeloid Leukemia Quizartinib